Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Sep;17(3):286-95.
doi: 10.1177/159101991101700302. Epub 2011 Oct 17.

Intra-arterial chemotherapy for malignant gliomas: a critical analysis

J-K Burkhardt  1 , H A Riina, B J Shin, J A Moliterno, C P Hofstetter, J A Boockvar
Affiliations
Review

Intra-arterial chemotherapy for malignant gliomas: a critical analysis

J-K Burkhardt et al. Interv Neuroradiol. 2011 Sep.

Erratum in

  • Interv Neuroradiol. 2011 Dec;17(4):506

Abstract

Intra-arterial (IA) chemotherapy for malignant gliomas including glioblastoma multiforme was initiated decades ago, with many preclinical and clinical studies having been performed since then. Although novel endovascular devices and techniques such as microcatheter or balloon assistance have been introduced into clinical practice, the question remains whether IA therapy is safe and superior to other drug delivery modalities such as intravenous (IV) or oral treatment regimens. This review focuses on IA delivery and surveys the available literature to assess the advantages and disadvantages of IA chemotherapy for treatment of malignant gliomas. In addition, we introduce our hypothesis of using IA delivery to selectively target cancer stem cells residing in the perivascular stem cell niche.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Sketch of our hypothesis on selective intra-arterial niche disruption (SIAND) and delivery A) Initially the BBB is closed and tumor stem-like cells located in the perivascular niche release VEGF and express VEGFR-2 receptors. B) The microcatheter is placed in the tumor supplying vessel and mannitol followed by bevacizumab is infused through the microcatheter. This opens the BBB and bevacizumab is able to enter into the perivascular niche to bind soluble VEGF. C) After IA treatment the BBB recloses and bevacizumab is trapped in the perivascular niche. VEGF signaling from tumor cells is blocked and VEGF signaling is diminished.
Figure 2
Figure 2
Sagittal (A) and coronal (E) post-gadolinium T1W images show a large left fronto-temporal located glioblastoma multiforme (arrow) in a 72-year-old man. On the un-subtracted DSA (B, F) the microcatheter tip (arrow) with regard to the craniotomy site (asterisk) indicates the point of chemotherapy injection. Contrast infusion into the distal branch of the left middle cerebral artery (C, G) as well as left anterior cerebral artery (D, H) supplying the GBM demonstrates the distribution of IA mannitol and temozolomide infusion in sagittal (C, D) and coronal (G, H) planes.
See this image and copyright information in PMC

References

    1. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003. - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996. - PubMed
    1. Andratschke N, Grosu AL, Molls M, et al. Perspectives in the treatment of malignant gliomas in adults. Anticancer Res. 2001;21:3541–3550. - PubMed
    1. Lefranc F, Rynkowski M, DeWitte O, et al. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv Tech Stand Neurosurg. 2009;34:3–35. - PubMed
    1. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466. - PubMed

Substances